Table II. Comparison of demographic and clinical status of patients included in the analysis vs those excluded due to lack of height measurement.

	Having at least 1 height measurement at follow-up
	No		Yes		Total
	n	%	n	%	n	%	χ2 P value
Total	123	100.0	899	100.0	1022	100.0
Sex
Male	61	49.6	415	46.2	476	46.6	.5006
Female	62	50.4	484	53.8	546	53.4
Race
Missing	1	0.8	5	0.6	6	0.6	.2194
White	86	69.9	543	60.4	629	61.5
Black	15	12.2	148	16.5	163	15.9
Hispanic	11	8.9	114	12.7	125	12.2
Other	10	8.1	89	9.9	99	9.7
Primary diagnosis
Biliary atresia	49	39.8	289	32.1	338	33.1	.3545
Other cholestasis	21	17.1	143	15.9	164	16.0
Fulminant liver failure	15	12.2	142	15.8	157	15.4
Metabolic disease	22	17.9	165	18.4	187	18.3
Cirrhosis	9	7.3	65	7.2	74	7.2
Other	7	5.7	95	10.6	102	10.0
Age at transplant
<6 mo	12	9.8	39	4.3	51	5.0	.0001
6-11 mo	28	22.8	103	11.5	131	12.8
1-4 y	21	17.1	230	25.6	251	24.6
5-12 y	40	32.5	386	42.9	426	41.7
13+ y	22	17.9	141	15.7	163	15.9
Length of follow-up
12 mo	7	5.7	99	11.0	106	10.4	.0411
24 mo	9	7.3	76	8.5	85	8.3
36 mo	21	17.1	84	9.3	105	10.3
48 mo	8	6.5	70	7.8	78	7.6
60 mo	6	4.9	76	8.5	82	8.0
72 mo	11	8.9	71	7.9	82	8.0
84 mo	5	4.1	93	10.3	98	9.6
96 mo	22	17.9	107	11.9	129	12.6
108 mo	17	13.8	90	10.0	107	10.5
120 mo	6	4.9	49	5.5	55	5.4
132 mo	8	6.5	49	5.5	57	5.6
144 mo	3	2.4	31	3.4	34	3.3
156 mo	0	0.0	4	0.4	4	0.4
Re-transplant
No	111	90.2	818	91.0	929	90.9	.7397
Yes	12	9.8	81	9.0	93	9.1
Received growth hormone therapy
Missing	78	63.4	363	40.4	441	43.2	.4774
No	44	35.8	529	58.8	573	56.1
Yes	1	0.8	7	0.8	8	0.8